Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...

A groundbreaking new study suggests that sotagliflozin, a drug recently approved to treat type 2 diabetes and kidney disease in people with additional cardiovascular risk factors, can also ...

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...

根据西奈山研究人员领导的一项国际临床试验的结果，最近被美国食品和药物管理局批准用于治疗伴有心血管危险因素的2型糖尿病和肾脏疾病的药物Sotagliflozin可以显著减少这些患者的心脏病发作和中风。 根据西奈山研究人员领导的一项国际临床试验的结果 ...

Sotagliflozin于2019年获得欧盟委员会批准上市用于胰岛素的辅助治疗，帮助控制1型糖尿病患者的血糖水平，去年5月，其获得美国FDA的批准，用于降低 ...

New research shows sotagliflozin is the only drug in its class to demonstrate these results. Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes ...

The US Food and Drug Administration eventually approved sotagliflozin in 2023 for the full spectrum of LVEF in patients who have heart failure with or without diabetes. The medication joined the two ...

When asked how sotagliflozin might help lower heart attack and stroke risk, Bhatt said it may be because the drug also blocks the SGLT1 (sodium-glucose cotransporter 1) receptor as well.

In such a scenario, a new study published in The Lancet Diabetes & Endocrinology has brought to light the benefits of sotagliflozin, approved for type 2 diabetes and kidney disease, in reducing the ...

Sotagliflozin, a newly FDA-approved medication ... and other cardiovascular risk factors,” adds Dr. Bhatt. “This drug was approved to reduce the risk of deaths from cardiovascular causes ...

Sotagliflozin belongs to a class of medications called gliflozins that help lower blood sugar levels by preventing the kidneys from reabsorbing glucose, allowing excess glucose to be excreted in urine ...